The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Complex repetitive discharge on electromyography as a risk factor for malignancy in idiopathic inflammatory myopathy

  • Kim, Na Ri (Department of Internal Medicine, Kyungpook National University School of Medicine) ;
  • Nam, Eon Jeong (Department of Internal Medicine, Kyungpook National University School of Medicine) ;
  • Kang, Jong Wan (Department of Internal Medicine, Kyungpook National University School of Medicine) ;
  • Song, Hyun Seok (Department of Neurology, Kyungpook National University School of Medicine) ;
  • Im, Churl Hyun (Department of Internal Medicine, Kyungpook National University School of Medicine) ;
  • Kang, Young Mo (Department of Internal Medicine, Kyungpook National University School of Medicine)
  • Received : 2013.08.03
  • Accepted : 2013.10.07
  • Published : 2014.11.01
⟨ Previous Next ⟩

Abstract

Background/Aims: We investigated the electromyography (EMG) findings and demographic, clinical, and laboratory features that may predict the development of malignancy in patients with idiopathic inflammatory myopathy (IIM). Methods: In total, 61 patients, 36 with dermatomyositis and 25 with polymyositis, were included. Patients were divided into those with and without malignancies, and comparisons were made between the groups in terms of their demographic, clinical, laboratory, and EMG findings. Results: The frequencies of malignancies associated with dermatomyositis and polymyositis were 22% and 8%, respectively. Patients with malignancies showed a significantly higher incidence of dysphagia (odds ratio [OR], 21.50; 95% confidence interval [CI], 3.84 to 120.49), absence of interstitial lung disease (ILD; OR, 0.12; 95% CI, 0.01 to 0.98), and complex repetitive discharge (CRD) on the EMG (OR, 26.25; 95% CI, 2.67 to 258.52), versus those without. After adjustment for age, dysphagia and CRD remained significant, while ILD showed a trend for a difference but was not statistically significant. Multivariate analysis revealed that the CRD conferred an OR of 25.99 (95% CI, 1.27 to 531.86) for malignancy. When the frequency of malignancy was analyzed according to the number of risk factors, patients with three risk factors showed a significantly higher incidence of malignancy, versus those with fewer than two (p = 0.014). Conclusions: We demonstrated for the first time that CRD on the EMG was an additional independent risk factor for malignancy in IIM. Further studies on a larger scale are needed to confirm the importance of CRD as a risk factor for malignancy in IIM.

Keywords

Acknowledgement

Supported by : Kyungpook National University

References

  1. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-347. https://doi.org/10.1056/NEJM197502132920706
  2. So MW, Koo BS, Kim YG, Lee CK, Yoo B. Idiopathic inflammatory myopathy associated with malignancy: a retrospective cohort of 151 Korean patients with dermatomyositis and polymyositis. J Rheumatol 2011;38:2432-2435. https://doi.org/10.3899/jrheum.110320
  3. Azuma K, Yamada H, Ohkubo M, et al. Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis and clinically amyopathic dermatomyositis. Mod Rheumatol 2011;21:178-183. https://doi.org/10.3109/s10165-010-0362-y
  4. Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001;357:96-100. https://doi.org/10.1016/S0140-6736(00)03540-6
  5. Buchbinder R, Forbes A, Hall S, Dennett X, Giles G. Incidence of malignant disease in biopsy-proven inflammatory myopathy: a population-based cohort study. Ann Intern Med 2001;134:1087-1095. https://doi.org/10.7326/0003-4819-134-12-200106190-00008
  6. Fardet L, Dupuy A, Gain M, et al. Factors associated with underlying malignancy in a retrospective cohort of 121 patients with dermatomyositis. Medicine (Baltimore) 2009;88:91-97. https://doi.org/10.1097/MD.0b013e31819da352
  7. Chen YJ, Wu CY, Shen JL. Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study. Br J Dermatol 2001;144:825-831. https://doi.org/10.1046/j.1365-2133.2001.04140.x
  8. Hunger RE, Durr C, Brand CU. Cutaneous leukocytoclastic vasculitis in dermatomyositis suggests malignancy. Dermatology 2001;202:123-126. https://doi.org/10.1159/000051611
  9. Uchino M, Yamashita S, Uchino K, et al. Muscle biopsy findings predictive of malignancy in rare infiltrative dermatomyositis. Clin Neurol Neurosurg 2013;115:603-606. https://doi.org/10.1016/j.clineuro.2012.07.019
  10. Paganoni S, Amato A. Electrodiagnostic evaluation of myopathies. Phys Med Rehabil Clin N Am 2013;24:193-207. https://doi.org/10.1016/j.pmr.2012.08.017
  11. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403-407. https://doi.org/10.1056/NEJM197502202920807
  12. Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 2002;46:626-636. https://doi.org/10.1067/mjd.2002.120621
  13. Andersson T, Alfredsson L, Kallberg H, Zdravkovic S, Ahlbom A. Calculating measures of biological interaction. Eur J Epidemiol 2005;20:575-579. https://doi.org/10.1007/s10654-005-7835-x
  14. Wakata N, Kurihara T, Saito E, Kinoshita M. Polymyositis and dermatomyositis associated with malignancy: a 30- year retrospective study. Int J Dermatol 2002;41:729-734. https://doi.org/10.1046/j.1365-4362.2002.01648.x
  15. Sigurgeirsson B, Lindelof B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis: a population-based study. N Engl J Med 1992;326:363-367. https://doi.org/10.1056/NEJM199202063260602
  16. Maugars YM, Berthelot JM, Abbas AA, Mussini JM, Nguyen JM, Prost AM. Long-term prognosis of 69 patients with dermatomyositis or polymyositis. Clin Exp Rheumatol 1996;14:263-274.
  17. Sampson JB, Smith SM, Smith AG, et al. Paraneoplastic myopathy: response to intravenous immunoglobulin. Neuromuscul Disord 2007;17:404-408. https://doi.org/10.1016/j.nmd.2007.01.004
  18. Levin MI, Mozaffar T, Al-Lozi MT, Pestronk A. Paraneoplastic necrotizing myopathy: clinical and pathological features. Neurology 1998;50:764-767. https://doi.org/10.1212/WNL.50.3.764
  19. Fellows LK, Foster BJ, Chalk CH. Clinical significance of complex repetitive discharges: a case-control study. Muscle Nerve 2003;28:504-507. https://doi.org/10.1002/mus.10425
  20. Trontelj J, Stalberg E. Bizarre repetitive discharges recorded with single fibre EMG. J Neurol Neurosurg Psychiatry 1983;46:310-316. https://doi.org/10.1136/jnnp.46.4.310

Cited by

  1. Autoimmune Myopathies : vol.22, pp.6, 2016, https://doi.org/10.1212/01.con.0000511070.50715.ab
  2. A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies vol.60, pp.6, 2014, https://doi.org/10.1093/rheumatology/keab166